Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000260417

Medchemexpress LLC Tenofovir amibufenamide | 1571076-26-0 | 99.7% | C22H31N6O5P | 10MG
SDP

Catalog No. 5000260417
Encompass_Preferred

Tenofovir amibufenamide is an orally active tenofovir prodrug used in antiviral research to inhibit hepatitis B virus (HBV). It is applied in preclinical studies of chronic hepatitis B to evaluate tenofovir-based antiviral activity and pharmacology.

  • Orally active tenofovir prodrug suitable for in vivo and in vitro studies.
  • Demonstrated inhibition of hepatitis B virus replication.
  • Used in chronic hepatitis B research applications.
  • High purity (99.7%).
  • Molecular formula C22H31N6O5P, molecular weight 490.49 g/mol.
  • Available in small research-scale quantities for preclinical use.

Catalog No. 50-002-60417 Supplier Medchemexpress LLC Supplier No. HY13745310MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Tenofovir amibufenamide is an orally active tenofovir prodrug used in antiviral research to inhibit hepatitis B virus (HBV). It is applied in preclinical studies of chronic hepatitis B to evaluate tenofovir-based antiviral activity and pharmacology.

  • Orally active tenofovir prodrug suitable for in vivo and in vitro studies.
  • Demonstrated inhibition of hepatitis B virus replication.
  • Used in chronic hepatitis B research applications.
  • High purity (99.7%).
  • Molecular formula C22H31N6O5P, molecular weight 490.49 g/mol.
  • Available in small research-scale quantities for preclinical use.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.